Some strains of lactic acid bacteria are reported to inhibit the growth of Helicobacter pylori and proposed to be useful to support so-called triple therapy for H. pylori. Although most strains must be alive to exert their anti-H. pylori activity, some lactobacilli strains are effective even when dead. One possible underlying mechanism of such an activity of non-living lactobacilli is reportedly co-aggregation with H. pylori. In this study, we found that a non-living heat-killed form of Lactobacillus johnsonii No.1088 (HK-LJ88) and also that of some other lactobacilli inhibited the growth of H. pylori in vitro. Furthermore, the number of H. pylori in the infected stomach of germ-free mice was significantly decreased by the repeated oral administration of HK-LJ88. Observation by scanning electron microscopy revealed that no co-aggregation had occurred between H. pylori and HK-LJ88; instead, deformations of H. pylori (e.g. disappearance of spiral, bending of cell body, coccoid formation, degradations, etc.) appeared after incubation for 24 h with HK-LJ88. These results suggest that HK-LJ88 inhibited H. pylori activity probably not by co-aggregation but by some unknown mechanism involving HK-LJ88's cell surface molecules and that even non-living lactobacilli are possibly useful to support H. pylori eradication therapy.
INTRODUCTION
Helicobacter pylori is a pathogenic bacterium infecting and being able to live in the stomach (Marshall and Warren 1984; Marshall et al. 1985; Morris and Nicholson 1987) . Helicobacter pylori causes chronic stomatitis and is now thought to be the main cause of stomach cancers (Peek 2002) . So it is crucial to eradicate H. pylori in order to keep a healthy stomach condition and to lower the future risk of stomach cancer. The standard therapy for an H. pylori infection is so-called triple therapy consisting of two antibiotics (e.g. clarithromycin and amoxicillin) and one 
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8 cells/mL of heat-killed lactobacilli were mixed with H. pylori, and the number of viable H. pylori was determined after 24-h cultivation at 37
• C under microaerobic conditions. (B) Dose-dependency of anti-H. pylori activity of HK-LJ88. Various concentrations of HK-LJ88 were incubated with three different initial concentrations of H. pylori (10 5 , 10 6 and 10 7 cfu/mL) for 24 h under microaerobic conditions.
proton-pump inhibitor (e.g. omeprazol) (Malfertheiner et al. 2007) . Recently, the emergence of H. pylori resistant to antibiotics has become problematic, reducing the rate of successful H. pylori eradication. However, the recent employment of different types of antibiotics (e.g. metronidazole) and a new potassiumcompetitive acid blocker (vonoprazan) have significantly increased the eradication rate above 90% or more (Nishizawa et al. 2015; Suzuki et al. 2016) .
Regarding lactic acid bacteria in relation to anti-H. pylori therapy, some strains (e.g. Lactobacillus johnsonii La1, L. gasseri OLL2716, L. delbrueckii supsp. bulgaricus, etc.) were reported to inhibit the growth of H. pylori in vitro and/or in vivo (Michetti et al. 1999; Felley et al. 2001; Sakamoto et al. 2001; Fukushima et al. 2004; Fujimura et al. 2006; Boyanova, Stephanova-Kondratenko and Mitov 2009; Kato-Mori et al. 2010) . Although there exist some controversies, intake of probiotics has been proposed, based on meta-analysis, to increase the rate of successful triple therapy for H. pylori (Dang et al. 2014) or at least to improve the adverse effects of diarrhea and nausea associated with triple therapy (Lu et al. 2016) . Anti-H. pylori activity of these strains of lactobacilli was reported to be elicited by living bacteria, but one report mentioned the anti-H. pylori activity of non-living lactobacilli. Namely, Holz et al. (2015) screened lactobacilli for the ability to co-aggregate with H. pylori, and they found a representative strain, L. reuteri DSM17648, to have strong co-aggregation ability. Notably, this strain could co-aggregate with H. pylori not only in its living state but also in its non-living state. They also examined the anti-H. pylori effect of non-living L. reuteri DSM17648 in a pilot clinical study and found it to be effective in humans (Holz et al. 2015) . So it is possible that there exist some other lactobacilli also having anti-H. pylori activity even when dead.
We recently found a new strain of lactobacilli, L. johnsonii No.1088 (LJ88) , that inhibits the growth of H. pylori in vitro and reduces the number of H. pylori infected in the stomach of human intestinal microbiota-associated mice (Aiba et al. 2015) . In this study, we examined whether or not the non-living, heatkilled form of LJ88 (HK-LJ88) and that of other lactobacilli would also have anti-H. pylori activity and found this to be the case. Next, we observed, by using scanning electron microscopy (SEM) technology, the mixture of HK-LJ88 and H. pylori to evaluate the possibility of co-aggregation with H. pylori as the responsible mechanism for this anti-H. pylori activity of HK-LJ88.
MATERIALS AND METHODS

Bacterial strains
Helicobacter pylori No.130 was isolated at Tokai University Hospital as described previously (Kabir et al. 1997) and cultured in brain/heart infusion broth (BD, NJ, USA) containing 5% horse serum (BHI-HS) under microaerobic conditions at 37
• C. LJ88 is a lactic acid bacterial strain isolated from the gastric juice of a healthy Japanese as described previously (Aiba et al. 2015) and cultured in de Man, Rogosa and Sharpe (MRS) broth (BD) at 37
and L. reuteri JCM1112) were obtained from Japan Collection of Microorganisms (RIKEN, Ibaraki, Japan) and cultured in MRS broth at 37
• C. For the experiment comparing various lactobacilli (Fig. 1A) , heat-killed preparations of lactobacilli were obtained by autoclaving bacterial suspensions in BHI broth (at about 5 × 10 9 cfu/mL) at 121
• C for 15 min. Regarding HK-LJ88
for other experiments, we used lyophilized powder of HK-LJ88, which had been prepared by autoclaving LJ88 in water and then freeze-dried. The number of HK-LJ88 in the lyophilized powder was determined by microscopically counting the number of LJ88 in its saline suspension with hemocytometer.
In vitro evaluation of anti-Helicobacter pylori activity
Helicobacter pylori No.130 were mixed with heat-killed preparations of lactobacilli in BHI-HS and then cultured for 24 h at 37
• C under microaerobic conditions. The number of viable H.
pylori was determined by counting colonies on BHI agar plates containing 7% horse serum, 25 μg/mL tetrazolium chloride, 2.5 units/mL polymyxin B and 2 μg/mL vancomycin B after the bacterial mixture had been spread on the plates and cultured for 3 days at 37
• C under microaerobic conditions. Numbers of H. pylori and lactobacilli used in each experiment were described in Results and Discussion section.
In vivo evaluation of anti-Helicobacter pylori activity in germ-free mice
Anti-H. pylori activity of HK-LJ88 in vivo was examined according to the method reported previously (Aiba et al. 2015; Komatsu et al. 2016) . Germ-free Balb/c mice purchased from Clea Japan, Inc. (Tokyo, Japan) were raised in Trexler-type flexible-film plastic isolators with sterile food and water, and used in this study. The outline of the study protocol is shown in Fig. 2A . Totally 26 germ-free Balb/c mice at 4 weeks of age (13 each of male and female) were infected with H. pylori No.130 by oral daily administration at a dose of 10 9 cfu/mice for four consecutive days.
Twenty-four days after the last H. pylori administration, six mice (three each of male and female) were sacrificed and their stomachs excised to determine the number of H. pylori before administration of HK-LJ88 ('before' group). At the same day, oral daily administration of HK-LJ88 at a dose of 6.8 × 10 8 cells/mice (in 0.5 mL PBS) was started (n = 10; 5 each of male and female) and continued for 21 days ('HK-LJ88' group). As the control, 0.5 mL PBS was administered for 21 days (n = 10; 5 each of male and female; 'PBS' group). On the day after the last administration of HK-LJ88, all mice were sacrificed, and the number of H. pylori in their stomachs was determined. The animal experiment in this study was carried out in accordance with the institutional guidelines of Tokai University.
Scanning electron microscopy
Helicobacter pylori No.130 (10 6 cfu/mL) was mixed with HK-LJ88
(10 8 cells/mL), and the mixture was cultured in BHI-HS for 24 h at 37
• C under microaerobic conditions. A nano percolater (Sem Pore; JEOL, Tokyo, Japan) was used to trap bacterial cells from 100 μL of culture solutions, and the trapped cells on the percolater membrane were washed with 0.1 M phosphate buffer (pH 7.4). The cells were then fixed with 2.5% glutaraldehyde for 30 min, washed with 0.1 M phosphate buffer (pH 7.4) and treated with 1% OsO 4 for 30 min. These processes were all performed at 4
• C. After dehydration with ethanol (stepwise elevation from 50%, through 70%, 90% and 95%, and finally to 100%), the membranes were transferred into tert-butyl alcohol and frozen. The frozen specimens were freeze-dried in JFD-310 freeze-drying device (JEOL) and then coated with osmium by use of an osmium coater (Meiwafosis, Tokyo, Japan). The SEM images were obtained with JSM-6510LV scanning electron microscope (JEOL).
RESULTS AND DISCUSSION
In vitro anti-Helicobacter pylori activity of various non-living, heat-killed lactobacilli Holz et al. (2015) . Although it would be interesting to elucidate the underlying mechanism by which each of these non-living heat-killed lactobacilli inhibited H. pylori, we decided to focus on our original LJ88 for the remainder of this study. Next, we examined the dose-dependent effects of HK-LJ88 on the viability of H. pylori at various initial concentrations of H. pylori (Fig. 1B) . In this experiment, we employed three different initial numbers of H. pylori, i.e. about 10 5 , 10 6 and 10 7 cfu/mL.
As shown in Fig. 1B , the lower the initial number of H. pylori, the stronger the inhibitory effect of HK-LJ88 on H. pylori viability; in either case, excessive numbers of HK-LJ88 compared with the initial number of H. pylori were necessary to efficiently inhibit H. pylori viability. Holz et al. (2015) reported that L. reuteri DSM17648 co-aggregated with H. pylori and inhibited its growth. They also reported that the co-aggregation occurred almost immediately (within 10 min) after mixing of both stationary-phase cells (probably same order of cell numbers). Therefore, some mechanism other than co-aggregation is possibly responsible at least for anti-H. pylori activity of HK-LJ88.
In vivo anti-Helicobacter pylori activity of HK-LJ88 evaluated in germ-free mice
Next we examined the anti-H. pylori activity of HK-LJ88 in vivo by using germ-free mice, as outlined in Fig. 2A . As shown in Fig. 2B , oral administration of HK-LJ88 at a concentration of 6.8 × 10 8 cells/mice significantly decreased the number of H. pylori that had infected the stomach of germ-free mice. Although we had already observed the anti-H. pylori effect of living LJ88 in vivo (Aiba et al. 2015) , this present report is the first to show the same in vivo effect by heat-killed LJ88. Regarding the anti-H. pylori activity of lactobacilli, some underlying mechanisms have been proposed: e.g. lactic acid secretion to lower the pH, production of antimicrobial products, competition for adhesion sites in the stomach, co-aggregation with H. pylori, and so on (Komatsu et al. 2016) . Although it has not yet been fully elucidated to date which mechanism is mainly responsible for this anti-H. pylori activity of lactobacilli in vivo, the first two mentioned above could be thought to contribute to the mechanism operating in living lactobacilli but not to that at work in non-living ones. The competition for adherent sites could contribute, in principle, in the case of both living and nonliving organisms. However, since in this study HK-LJ88 administration was started after a successful H. pylori infection, this competition scenario might not be the case. The last one, coaggregation, is the most probable, because another strain of lactobacilli, L. reuteri DSM17648, with strong co-aggregation activity with H. pylori, was reported to be effective when orally administered as a non-living form in a clinical setting (Holz et al. 2015) . Therefore, next we examined the possibility of co-aggregation as the mechanism of HK-LJ88 to inhibit H. pylori.
Observation by SEM of anti-Helicobacter pylori activity of HK-LJ88 Holz et al. (2015) published SEM images of a mixture of H. pylori and L. reuteri DSM17648, in which a kind of checkerwise structure consisting of both bacteria was observed. They also reported that such strains of lactobacilli with the property to coaggregate with H. pylori formed aggregates almost immediately after the two had been mixed (within 10 min). So first we examined whether a kind of flocculated structures would be formed by mixing HK-LJ88 and H. pylori. However, we could not observe by the naked eye any such structures within 10 min or even after an overnight incubation. So next we examined the detailed structure of HK-LJ88 and H. pylori mixture using SEM technology. Figure 3 shows a low-magnification (×4000) image of a bacterial mixture (about 10 6 and 10 8 cells for H. pylori and HK-LJ88, respectively) after incubation for 24 h at 37
• C under microaerobic conditions, which image indicated no checkerwise structures reflecting co-aggregation. Figure 4 shows typical scenes obtained from SEM observations (×15 000) after incubation of H. pylori with HK-LJ88 for 24 h. Figure 4A and B present the SEM images obtained without mixing of HK-LJ88 and H. pylori, i.e. Fig. 4A and B were taken solely of H. pylori and HK-LJ88, respectively. Figure 4A shows the typical spiral shapes of H. pylori and Fig. 4B the rod-shaped structures of HK-LJ88. Figure 4C -E are typical images of the mixture of HK-LJ88 and H. pylori after a 24-h incubation, in which, again, no signs of co-aggregation were observed. In all three fields, the rod-shaped structures of HK-LJ88 were almost the same and without any deformations. On the contrary, the shape of H. pylori was largely affected by the presence of HK-LJ88. Figure 4C shows that the spiral shape of H. pylori had become a bended one, and Fig. 4D shows the appearance of so-called coccoid forms of H. pylori (Kusters et al. 1997; Willen et al. 2000) . The field in Fig. 4E reveals H. pylori cells with margins dispersed and largely damaged, including some segmentations.
These results strongly suggest that anti-H. pylori effect of HK-LJ88 was not caused by co-aggregation with H. pylori. Instead, the presence of HK-LJ88 itself might have affected the viability of H. pylori. As was shown in Fig. 1B , an excessive number of HK-LJ88 compared with that of H. pylori was necessary to give rise to its anti-H. pylori activity. Thus, one possibility might be contact made between HK-LJ88 and H. pylori. Namely, some cellsurface molecules and/or their distribution on the cell surface of HK-LJ88 attacked H. pylori. Another possibility might be soluble factors derived from HK-LJ88 (either of intracellular or cell surface). However, since sonication of HK-LJ88 in BHI broth before mixing with H. pylori, which might have increased soluble factors derived from cells, weakened its anti-H. pylori activity in vitro depending on the time duration of sonication (data not shown), such participation of soluble factors might not be so probable. To our knowledge, this is the first report suggesting anti-H. pylori activity of non-living, heat-killed lactobacilli not by co-aggregation, though further studies will be necessary to fully understand the molecular mechanism of this anti-H. pylori activity of HK-LJ88 and that of other effective lactobacilli as well.
Although a meta-analysis study showed the possibility that probiotics could increase the rate of successful triple therapy (Dang et al. 2014) , another meta-analysis one denied such a merit of probiotics (Lu et al. 2016) . Since these studies analyzed the clinical results with various probiotic strains as a whole, it is possible that the difference of strains should have been taken into account to understand the supportive nature of individual probiotic strains in anti-H. pylori therapy. Regarding the probable merit of non-living lactobacilli including HK-LJ88 to support triple therapy, future clinical studies will be necessary to have conclusive results.
CONCLUSIONS
HK-LJ88 and some other heat-killed lactobacilli inhibited the growth of Helicobacter pylori in vitro. Moreover, HK-LJ88 exerted anti-H. pylori activity even in vivo in germ-free mice. SEM observation revealed that no co-aggregation occurred between H. pylori and HK-LJ88 when the two were mixed, whereas deformations of H. pylori (e.g. disappearance of spiral shape, bending of cell body, coccoid formation, degradations, etc.) had occurred. Therefore, HK-LJ88 might have inhibited H. pylori activity not by co-aggregation. These results suggest that even non-living lactobacilli including HK-LJ88 may possibly be useful to support H. pylori eradication therapy as do some probiotics.
